FY2025 Earnings Forecast for ATXS Issued By Lifesci Capital

Astria Therapeutics, Inc. (NASDAQ:ATXS) – Research analysts at Lifesci Capital decreased their FY2025 EPS estimates for shares of Astria Therapeutics in a research report issued on Tuesday, March 11th. Lifesci Capital analyst S. Slutsky now expects that the biotechnology company will post earnings per share of ($1.97) for the year, down from their previous estimate of ($1.95). The consensus estimate for Astria Therapeutics’ current full-year earnings is ($1.65) per share.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01.

Several other equities research analysts have also commented on ATXS. Citizens Jmp upgraded shares of Astria Therapeutics to a “strong-buy” rating in a research note on Friday, January 31st. JMP Securities began coverage on shares of Astria Therapeutics in a research note on Friday, January 31st. They issued an “outperform” rating and a $26.00 price objective for the company. Wedbush reiterated an “outperform” rating and issued a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a research note on Wednesday. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, March 11th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $26.67.

Astria Therapeutics Stock Performance

Shares of NASDAQ ATXS opened at $6.45 on Friday. Astria Therapeutics has a fifty-two week low of $5.73 and a fifty-two week high of $16.90. The stock has a market cap of $364.00 million, a price-to-earnings ratio of -3.09 and a beta of 0.69. The firm’s 50-day simple moving average is $7.14 and its 200 day simple moving average is $9.51.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently modified their holdings of the stock. FMR LLC increased its stake in shares of Astria Therapeutics by 29.2% during the 3rd quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after purchasing an additional 1,767,714 shares during the last quarter. RA Capital Management L.P. increased its stake in shares of Astria Therapeutics by 1.2% during the 3rd quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares during the last quarter. Vestal Point Capital LP increased its stake in shares of Astria Therapeutics by 4.5% during the 4th quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock worth $37,369,000 after purchasing an additional 180,000 shares during the last quarter. Fcpm Iii Services B.V. purchased a new stake in shares of Astria Therapeutics during the 4th quarter worth approximately $25,680,000. Finally, Vanguard Group Inc. increased its stake in shares of Astria Therapeutics by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 2,677,353 shares of the biotechnology company’s stock worth $23,936,000 after purchasing an additional 41,833 shares during the last quarter. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.